By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


AcelRx Pharmaceuticals 

575 Chesapeake Drive

Redwood City  California  94063  U.S.A.
Phone: 650-216-3500 Fax: 650-216-6500




Company News
AcelRx Pharmaceuticals (ACRX)'s Zalviso Met Primary Endpoint In Phase 3 Study 10/22/2014 5:51:25 AM
AcelRx Pharmaceuticals (ACRX) Provides Update On Its Patent Portfolio For Zalviso™ And Its Proprietary Platform Technologies 10/16/2014 7:47:49 AM
AcelRx Pharmaceuticals (ACRX) Announces Multiple Sublingual Sufentanil Data Presentations At The American Society Of Anesthesiologists Meeting 10/10/2014 9:25:49 AM
Harwood Feffer LLP Announces Investigation Of AcelRx Pharmaceuticals (ACRX) 10/8/2014 8:22:59 AM
Federman & Sherwood Announces Filing Of Securities Class Action Lawsuit Against AcelRx Pharmaceuticals (ACRX) 10/7/2014 10:23:33 AM
AcelRx Pharmaceuticals (ACRX) Release: Sufentanil Sublingual Tablet System Study Results To Be Presented At The International Association For The Study Of Pain Meeting 10/6/2014 7:31:58 AM
AcelRx Pharmaceuticals (ACRX) Provides Regulatory Update On Zalviso™ 9/26/2014 9:52:07 AM
AcelRx Pharmaceuticals (ACRX) Announces Publication Of Manuscript Analyzing Cost Of Intravenous Patient-Controlled Analgesia With Opioids 9/10/2014 8:37:50 AM
AcelRx Pharmaceuticals (ACRX) Announces Publication Of Sufentanil Sublingual Tablet System Vs. Intravenous Patient-Controlled Analgesia With Morphine For Postoperative Pain Study Results 9/5/2014 10:39:39 AM
AcelRx Pharmaceuticals (ACRX) To Participate In Two Upcoming Investor Events 8/27/2014 8:22:40 AM